^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GSK5733584
i
Other names: GSK5733584, HS-20089, GSK 5733584, HS 20089, GSK-5733584, HS20089
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
GSK, Jiangsu Hansoh Pharma
Drug class:
Topoisomerase I inhibitor, B7-H4-targeted antibody-drug conjugate
Related drugs:
16d
BEHOLD-1: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=385, Recruiting, GlaxoSmithKline | N=240 --> 385 | Trial primary completion date: Oct 2026 --> Feb 2027
Enrollment change • Trial primary completion date
|
GSK5733584
1m
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=157, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
Avastin (bevacizumab) • docetaxel • AiTan (rivoceranib) • albumin-bound paclitaxel • irinotecan • GSK5733584 • GSK5764227 • HS-10502
3ms
B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review. (PubMed, J Immunother Precis Oncol)
B7-H4-directed agents, particularly antibody-drug conjugates (ADCs) like puxitatug samrotecan (AZD8205), felmetatug vedotin (SGN-B7H4V), and GSK5733584, have demonstrated early clinical activity with promising response rates in triple-negative breast cancer (TNBC). Combination strategies, such as ADCs with anti-PD-1 or PARP inhibitor therapies, have also shown enhanced tumor regression in preclinical models and are the subject of several ongoing clinical trials. This review highlights the current landscape of B7-H4-targeted agents, their progress in clinical trials, and the potential for combination approaches to improve outcomes in B7-H4-expressing cancers.
Review • Journal
|
VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
|
puxitatug samrotecan (AZD8205) • felmetatug vedotin (PF-08046048) • GSK5733584
4ms
BEHOLD-2: A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=360, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting
Enrollment open
|
GSK5733584
4ms
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov)
P3, N=468, Not yet recruiting, Hansoh BioMedical R&D Company
New P3 trial
|
paclitaxel • doxorubicin hydrochloride • topotecan • GSK5733584
5ms
BEHOLD-2: A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=360, Not yet recruiting, GlaxoSmithKline | Phase classification: P1 --> P1/2 | Trial primary completion date: Jan 2027 --> Sep 2027
Phase classification • Trial primary completion date
|
GSK5733584
5ms
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=240, Recruiting, GlaxoSmithKline | Trial completion date: Jan 2027 --> Jun 2027
Trial completion date
|
GSK5733584
6ms
A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors (clinicaltrials.gov)
P1, N=360, Not yet recruiting, GlaxoSmithKline
New P1 trial
|
GSK5733584
6ms
HS-10502 Combination Treatment in Patients with Advanced Solid Tumors (clinicaltrials.gov)
P1, N=154, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
New P1 trial
|
Avastin (bevacizumab) • docetaxel • AiTan (rivoceranib) • albumin-bound paclitaxel • irinotecan • GSK5733584 • GSK5764227 • HS-10502
10ms
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=240, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
GSK5733584
12ms
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=1048, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
Avastin (bevacizumab) • cisplatin • carboplatin • Ariely (adebrelimab) • GSK5733584
1year
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=240, Not yet recruiting, GlaxoSmithKline
New P1 trial • Metastases
|
GSK5733584
over1year
A Study of HS-20089 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=177, Recruiting, Shanghai Hansoh Biomedical Co., Ltd | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Metastases
|
GSK5733584
over1year
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer (clinicaltrials.gov)
P2, N=460, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
Enrollment open
|
GSK5733584
over1year
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=1048, Not yet recruiting, Hansoh BioMedical R&D Company
New P1 trial • Metastases
|
Avastin (bevacizumab) • cisplatin • carboplatin • Ariely (adebrelimab) • GSK5733584
almost2years
First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors (ESMO 2023)
The patient achieving PR with the longest treatment duration of 403 days remains on treatment in 0.7 mg/kg cohort. Conclusions Based on data from the ongoing study, HS-20089 was well tolerated and showed antitumor activities in advanced solid tumors, with encouraging clinical efficacy in TNBC.
Clinical • P1 data • Metastases
|
VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
|
GSK5733584
Share via
